Elderly Women Benefit From Alendronate After Abaloparatide

By Reuters Staff

July 27, 2020

NEW YORK (Reuters Health) - Sequential therapy with abaloparatide (ABL) and alendronate (ALN) is safe and effective for maintaining bone mineral density (BMD) in women 80 and older, according to a new post-hoc analysis.

"This approach represents a real-world therapeutic strategy for reducing fracture risk in older postmenopausal women with osteoporosis and a high risk of fracture," Dr. Susan L. Greenspan of the University of Pittsburgh and colleagues conclude in their report in Menopause.

The 18-month ACTIVE (ABL Comparator Trial In Vertebral Endpoints) trial found ABL increased bone mineral density (BMD) and reduced fracture risk, with similar effects in patients 80 and older compared to younger patients.

In the new study, Dr. Greenspan and her team looked at the oldest patients participating in the ACTIVExtend study, in which ACTIVE participants took open-label alendronate (ALN) for an additional 24 months. There were 29 women age 80 and older in the ABL/ALN group and 27 in the placebo/ALN group.

At week 43, lumbar spine, total hip and femoral neck BMD had increased by 17.2%, 5.3% and 4.6%, respectively, for the ABL/ALN group, versus 8.6%, 3.0% and 3.1%, respectively, for the placebo/ALN group.

There were no new vertebral fractures in the ABL/ALN group during the study, and one new nonvertebral fracture, while there was one vertebral and two nonvertebral fractures in the placebo/ALN patients,

"Our results highlight sequential therapy of ABL followed by ALN as an effective therapy to prevent bone loss in older women, a population that is at increased risk for osteoporosis and the clinical consequences associated with osteoporosis," Dr. Greenspan and her team write.

While the number of adverse events (AE) was too small to draw conclusions between the two groups, they note, "AE types and rates were comparable to those observed in the overall population and no new or unexpected safety signals were observed in either group."

Dr. Greenspan was not available for an interview by press time.

SOURCE: https://bit.ly/2D1JRXW Menopause, online July 13, 2020.